A new health care package from House Republicans aims to tackle rising costs but leaves out critical ACA subsidies. As debates heat up, can they deliver real change for Americans?
As Congress races against time, House Republicans present a new health care plan that could reshape coverage options, but will it satisfy critics and prevent rising costs for Americans?
House Republicans are set to vote on health care next week but have excluded enhanced ACA subsidies from their plans. This could lead to their expiration, despite some moderates pushing for an extension to alleviate rising premiums.
In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
A groundbreaking new method utilizes RFdiffusion and deep learning to design antibodies that target specific epitopes, revolutionizing antibody therapeutics and enhancing their effectiveness against diseases.
In a bold move, Pfizer has filed a lawsuit against Novo Nordisk and Metsera, claiming their merger violates antitrust laws and threatens competition in the obesity drug market.
As demand for weight loss and diabetes drugs surges, Eli Lilly and Novo Nordisk dominate the market. Discover the challenges, competition, and future of this booming industry.
As 'Bugonia' fades to black, viewers are left in stunned silence, grappling with Yorgos Lanthimos' unsettling narrative. The film's perplexing themes and a divisive ending spark heated discussions among audiences.
A staggering recall of over half a million blood pressure medication bottles has been announced due to unsafe levels of cancer-causing chemicals. Are you affected? Find out more!
Eli Lilly's stock surged 3.9% after an outstanding Q3 earnings report, surpassing analysts' expectations with $7.02 per share and $17.6 billion in sales. The company raised its yearly guidance, signaling strong growth potential.